Notice of Correction to RFA-DA-19-009, Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed)

Notice Number: NOT-DA-19-009

Key Dates
Release Date: November 15, 2018

Related Announcements
RFA-DA-19-009

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The reason for this Notice is to clarify the purpose in RFA-DA-19-009, Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed).  

Current Language:

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Purpose

Proposed projects MUST include the following components.  Applications which lack these three components will be considered non-responsive to the FOA and will not be reviewed.The major thrust of the project MUST involve exploitation of induced microglia and cerebral organoids generated from patient derived iPSC lines to better understand the molecular and cellular mechanisms of HIV-Associated Neurocognitive Disorder (HAND). At least one aim or sub-aim MUST also involve either 1. opioid, cannabinoid, methamphetamine, nicotinic, dopaminergic, or other signaling pathways relevant to addictive substance use, or 2. exposure to addictive substances, or 3. analysis of samples from patients that have used addictive substances or have SUDs.  Addictive substances of interest include: opioids, nicotine, cocaine, methamphetamine, stimulants, prescription drugs, cannabinoids, alcohol, or combinations of these drugs.  Applications focused solely on alcohol exposure will be considered non-responsive to this FOA.” 

New Language:

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Purpose

Proposed projects MUST include all of the following components: 1) cerebral organoids containing microglia induced from iPSCs; 2) cerebral organoids containing microglia induced from iPSCs infected with HIV; 3) cerebral organoids containing microglia induced from iPSCs that have been exposed to a drug of abuse; 4) cerebral organoids containing microglia induced from iPSCs that have been infected with HIV and exposed to a drug of abuse.  iPSCs may be derived from normal health individuals, individuals affected with a substance use disorder (SUD), or individuals infected with HIV; or HIV infected individuals with a SUD.  Addictive substances of interest include: opioids, nicotine, cocaine, methamphetamine, stimulants, prescription drugs, cannabinoids, alcohol, or combinations of these drugs.  Applications focused solely on alcohol exposure will be considered non-responsive to this FOA.

HIV +

HIV –

 Drug of Abuse +

Drug +

HIV +

Drug +

HIV –

Drug of Abuse –

Drug –

HIV +

Drug –

HIV –

Further Clarification:

Investigators proposing to create iPSC derived only from cells of individuals not suffering from a substance use disorder and are derived from normal healthy individuals will be considered responsive to RFA-DA-19-009, Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-009.html , and to the accompanying RFA-DA-19-010 , Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R21 - Clinical Trials Not Allowed)https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-010.html .  Investigators still must create cerebral organoids containing microglia induced from iPSCs that are subsequently infected with HIV.  At least one aim must examine the effect of a drug of abuse on these organoids containing microglia in the presence and absence of HIV infection.  Applicants may still propose derivation of iPSC from individuals with a substance use disorder or individual infected with HIV.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Da-Yu Wu, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-4649
Email: wudy@mail.nih.gov